Literature DB >> 27053697

Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.

Rainer Kozlik-Feldmann1, Georg Hansmann2, Damien Bonnet3, Dietmar Schranz4, Christian Apitz5, Ina Michel-Behnke6.   

Abstract

Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a complex disease that presents with a broad spectrum of morphological and haemodynamic findings of varying severity. Recently, the aspect of paediatric pulmonary hypertensive vascular disease (PPHVD) has been introduced to expand the understanding of the full spectrum of pulmonary hypertension and increased pulmonary vascular resistance. Evaluation and treatment of PAH-CHD/PPHVD-CHD can be divided into in different topics. First, defining criteria for operability and initiation of advanced therapies preoperatively and postoperatively is an unresolved issue. Second, management of Eisenmenger syndrome is still an important question, with recent evidence on the severity of the disease and a more rapidly progressive course than previously described. Third, the Fontan circulation with no subpulmonary ventricle requires a distinct discussion, definition and classification since even a mild rise in pulmonary vascular resistance may lead to the so-called failing Fontan situation. Patients with CHD and single-ventricle physiology (Fontan/total cavopulmonary anastomosis) require a particularly stepwise and individualised approach. This consensus statement is on the current evidence for the most accurate evaluation and treatment of increased pulmonary artery pressure and resistance, as well as ventricular dysfunction, in children with congenital heart defects, and provides according practical recommendations. To optimise preoperative and postoperative management in patients with PAH-CHD, diagnostic and treatment algorithms are provided. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27053697     DOI: 10.1136/heartjnl-2015-308378

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  14 in total

1.  EXPRESS: Parameters associated with outcome in pediatric patients with congenital heart disease and pulmonary hypertension subjected to combined vasodilator and surgical treatments.

Authors:  Ana Maria Thomaz; Luiz Junya Kajita; Vera D Aiello; Leína Zorzanelli; Filomena Rbg Galas; Cleide G Machado; Miguel Barbero-Marcial; Marcelo B Jatene; Marlene Rabinovitch; Antonio Augusto Lopes
Journal:  Pulm Circ       Date:  2019-02-26       Impact factor: 3.017

Review 2.  Pregnancy in adults with congenital heart disease.

Authors:  Elvin Zengin; Götz Mueller; Stefan Blankenberg; Yskert von Kodolitsch; Carsten Rickers; Christoph Sinning
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

3.  The effect of distal pulmonary obstruction or elevated atrial pressures on pulmonary flow and pulmonary vascular disease: a mathematical flow circuit analogy model-based analysis.

Authors:  Balram Babu Rajanbabu; Raviraju Chigullapally
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-04-26

4.  Right ventricular base/apex ratio in the assessment of pediatric pulmonary arterial hypertension: Results from the European Pediatric Pulmonary Vascular Disease Network.

Authors:  Martin Koestenberger; Alexander Avian; Andreas Gamillscheg; Hannes Sallmon; Gernot Grangl; Ante Burmas; Sabrina Schweintzger; Stefan Kurath-Koller; Gerhard Cvirn; Georg Hansmann
Journal:  Clin Cardiol       Date:  2018-08-18       Impact factor: 2.882

5.  Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study.

Authors:  Shutan Liao; Dongsheng Li; Zheng Hui; Craig S McLachlan; Yang Zhang
Journal:  ERJ Open Res       Date:  2018-08-22

Review 6.  Pulmonary hypertension in congenital heart disease.

Authors:  Emma Pascall; Robert Mr Tulloh
Journal:  Future Cardiol       Date:  2018-05-24

7.  Chronic dosing with metformin plus bosentan decreases in vitro pulmonary artery contraction from isolated arteries in adults with pulmonary hypertension.

Authors:  Shutan Liao; Dongsheng Li; Zheng Hui; Craig S McLachlan; Yang Zhang
Journal:  J Cardiovasc Thorac Res       Date:  2019-08-26

Review 8.  Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway.

Authors:  Maurice Beghetti; Matthias Gorenflo; D Dunbar Ivy; Shahin Moledina; Damien Bonnet
Journal:  Pediatr Pulmonol       Date:  2019-07-16

Review 9.  Echocardiographic Evaluation of Transitional Circulation for the Neonatologists.

Authors:  Yogen Singh; Cécile Tissot
Journal:  Front Pediatr       Date:  2018-05-15       Impact factor: 3.418

10.  The impact of trisomy 21 on treatment modalities and outcome in adults with congenital heart disease in Switzerland.

Authors:  Judith Johannes; Matthias Greutmann; Daniel Tobler; Judith Bouchardy; Dominik Stambach; Kerstin Wustmann; Fabienne Schwitz; Markus Schwerzmann
Journal:  Pulm Circ       Date:  2018-10-19       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.